Antithrombotic Treatments in Residents with SARSCoV-2/COVID-19 in PALTC

Get It!

1.25 CME / 1.25 CMD Clinical / 1.25 MOC

This session will concentrate on current and potential anticoagulation strategies for residents in the PALTC settings. Potential topics include association between COVID-19 and thromboembolism, chronic anticoagulation or antiplatelet treatment, screening/assessment for venous thromboembolism and managing antithrombotic therapy among residents with COVID-19 in PALTC. Evidence based approaches will be presented to show clinical gaps in PALTC settings and share possible future solutions for this unique population. Risks and benefits and case-based approaches will be used for an interactive session.

Learning Objectives:

At the completion of this session, learners will be able to:
  • Review current guidelines recommendations for anticoagulation in persons with COVID-19 in PALTC settings.
  • Discuss thrombotic risk factors affecting decision making about anticoagulation in the PALTC population.
  • Define unique risk and benefits of anticoagulation in the PALTC population with COVID-19.
  • Describe thromboembolic risks after COVID-19 vaccination.

Presenters:

hnStefan Gravenstein, MD, MPH, is a geriatrician that has served as director or chief of geriatrics in three academic institutions, now the Director, Division of Geriatrics and Palliative Medicine at the Alpert Medical School of Brown University and Associate Director of the Center on Innovation in Long-Term Services and Supports at the Providence Veterans Administration Medical Center. Dr. Gravenstein has a long-standing interest in immunity, inflammation, cardiovascular outcomes and aging especially in the context of infection, vaccines and the long-term care setting.

hnYasin Abul, MD, is an Assistant Professor of Medicine, Clinician Educator at Division of Geriatric and Palliative Medicine, Warren Alpert Medical School of Brown University. Dr.Abul has clinical fellowship trainings in Pulmonary, Infectious Diseases and Geriatric Medicine. He has numerous publications in pulmonary vascular diseases and pulmonary embolism and his research interest area is venous thromboembolism, risk stratification and biomarkers in COVID-19. Dr. Abul is also an advanced research fellow at VA Office of Academic Affiliations Fellowship Program and doing Master Degree of Clinical Translational Research at Brown School of Public Health.

hnElie Saade, MD, MPH, FIDSA, is an Associate Professor of Medicine at the University School of Medicine. He is board-certified in Internal Medicine, Geriatrics, and Infectious Diseases and teaches medical students, residents, and fellows on clinical issues at the intersection of Geriatrics and ID. He is interested in the prevention and treatment of infections in the elderly, especially viral respiratory infections as well as hospital-acquired infections.

hnNadia Mujahid, MD, CMD, AGSF, is an Associate Professor of Medicine at the Warren Alpert Medical School of Brown University. She is the Co-Director of the Geriatric Fracture Program at Rhode Island Hospital and is the Medical Director for the Transitional Care Unit at Steere House Nursing and Rehabilitation Center. She teaches residents and Geriatric Medicine Fellows in hospital as well as subacute and long term care settings. She is the Course Director for the Geriatrics Orthopedic Trauma rotation for the Geriatric Medicine Fellows. She is a member of the AGS and AMDA and is the recepient of the Beckwith Family Teaching award. She practices in inpatient, outpatients and nursing home setting.

Credit Information:

Activity Created 3/2023
Credits Available Until 3/2026

  • 1.25 CME
  • 1.25 CMD Clinical
  • 1.25 MOC

 

 

Credit Statements: 

 

CME: AMDA – The Society for Post-Acute and Long-Term Care Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AMDA – The Society for Post-Acute and Long-Term Care Medicine for Post-Acute and Long-Term Care Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CMD: This self-study activity has been pre-approved by the American Board of Post-Acute and Long-Term Care Medicine (ABPLM) for a total of 1.25 clinical hour(s) toward certification or recertification as a Certified Medical Director (CMD) in post-acute and long-term care medicine. The CMD program is administered by the ABPLM. Each physician should claim only those hours of credit actually spent on the activity.

ABIM Maintenance of Certification (MOC): Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points and patient safety credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Visit the Continuing Education page for information on if and how you can claim credit/hours for AMDA’s education.

Disclosure Information:
The Society requires the disclosure of all speaker/faculty/planner’s relevant financial relationships; presence of off-label use of a device or medication; and discussion of any experimental, new or evolving topic prior to each accredited education activity.

If the learner perceives any bias toward a commercial product or service, advocation of unscientific approaches to diagnosis or therapy, or recommendation, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients please report this to the Society’s staff.

  • Julie Gammack, MD, CMD (Planner & Speaker): Stockholder: Amarin
  • Kenya Rivas Velasquez, MD, CMD, FAAFP (Planner & Speaker): OptumRx: Stockholder
  • Stefan Gravenstein, MD, MPH: Genentech: Advisory Board; Genentech: Contracted Research; GlaxoSmithKline: Advisory Board; GlaxoSmithKline: Honorarium; Icosavax: Advisory Board; Janssen: Advisory Board; Janssen: Speaker's Bureau; Longevoron: Data Safety Monitoring Board; Merck: SRC (Ended, January 1, 2020); Moderna: Consultant; Novavax: Advisory Board; Pfizer: Advisory Board; Pfizer: Contracted Research; Pfizer: Speaker's Bureau; Sanofi: Advisory Board; Sanofi: Contracted Research; SciClone: Data Safety Monitoring Board; Seqirus: Contracted Research; Seqirus: Speaker's Bureau; Sequirus: Contracted Research; Sequirus: Honorarium; VaxArt: Advisory Board
  • Elie Saade, MD, MPH, FIDSA (Speaker): Janssen Pharmaceuticals: Contracted Research (Ended, December 31, 2020); Janssen Pharmaceuticals: Clinical trial steering committee; Janssen Pharmaceuticals: Speaker's Bureau; Pfizer: Clinical Trial Investigator; Pfizer: Contracted Research; Sanofi Pasteur: Contracted Research (Ended, March 31, 2022)
  •  
  • All other planners, speakers, and AMDA staff have no relationships with ineligible companies.

All relevant financial relationships have been identified and mitigated.

Get It!